Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP

Corbus Pharmaceuticals — Investor Presentation (August 2024)

75 slides from Corbus Pharmaceuticals's investor presentation, Aug 6, 2024

  1. Slide 1: Connecting Innovation to Purpose

    Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation August 6, 2024 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, prod

  3. Slide 3: Investment Summary

    Investment Summary $147M Cash, cash equivalents and investments as of June 30, 2024. Approximately 11.5M Common Shares Outstanding (12.5M Fully-Diluted Shares) Nectin-4 targeting ADC for treatment of solid tumors Oral CB1R inverse agonist to treat obesity TGFβ blocker Anti-⍺vβ8 integrin mAb for trea

  4. Slide 4: A Diversified Pipeline with Differentiated Clinical Risk Profiles

    Therapy Disease Indication Sponsor Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones Next-Generation Nectin-4 targeting ADC CRB-701 Next-generation Nectin-4 targeting ADC Nectin-4 positive solid tumors CSPC (China) Cohort 6 Expanding Corbus (US + Europe) First Patient Dosed Anti-Integrin mAb CRB-601 A

  5. Slide 5: CRB-701 Next Generation Nectin-4 Targeting ADC

    CRB-701 Next Generation Nectin-4 Targeting ADC

  6. Slide 6: PADCEV Projected to Reach Up to ~$5B in Global Sales

    PADCEV® Projected to Reach Up to ~$5B in Global Sales by 2028 Sources: 1. SGEN press release, October 2023, 2. Evaluate Pharma PADCEV® Global Projected Revenues in UC/Bladder2 $5B Latest Padcev® Q3 revenues 1 22nd October 2023 2 ® Groundbreaking EV-302 Trial Significantly Extends Overall Survival an

  7. Slide 7: Does Tolerability for Padcev Impact Clinical Adoption?

    Does Tolerability for Padcev® Impact Clinical Adoption? Source(s): PADCEV® Prescribing Information as of Apr 2023. Duration of Response ~5 months 47% Rate of Serious Adverse Events (SAEs) 61% Dose Interruptions 34% Dose Reductions 17% Dose Discontinuations Revised: 4/2023 PADCEV® Prescribing Informa

  8. Slide 8: PADCEV is Associated with Skin Toxicities and Peripheral Neuropathy

    PADCEV® is Associated with Skin Toxicities and Peripheral Neuropathy Source(s): 1. PADCEV® Prescribing Information Dec 2023. 2.Rosenberg et al. 2020 Adverse Events (% of Patients) ® A Black Box Warning1 Greater than 25% of PADCEV® discontinuations are linked to peripheral neuropathy 2 PADCEV® + Keyt

  9. Slide 9: Is the 2nd Generation Seagen Linker the Cause?

    ADC drug TAA Average DAR Skin Rash Peripheral Neuropathy Padcev® Enfortumab vedotin Nectin-4 3.8 Adcetris® Brentuximab vedotin CD30 4 Tivdak® Tisotumab vedotin TF 4 Polivy® Polatuzumab vedotin CD79B 3.5 Aidixi® Disitamab vedotin HER2 4 Is the 2nd Generation Seagen® Linker the Cause? Padcev® Val-Cit

  10. Slide 10: PADCEV Requires Frequent Dosing and Real-world Usage Differs from Label

    6 months of therapy = ~ 54 hours of total clinic time / patient Real-world use, dose intensity, and adherence to Padcev® PADCEV® Requires Frequent Dosing and Real-world Usage Differs from Label Source(s): 1. PADCEV® Prescribing Information as of Dec 2019, 2. Redacted from Tsingas et al., ASCO 2023 M

  11. Slide 11: Designing a Nectin-4 ADC Intended to Address PADCEV Unmet Needs

    Nectin-4 targeting ADC for treatment of solid tumors Extend ADC half-life  Reduce dosing frequency Lower DAR + longer half-life  Dose higher than PADCEV® Compliance Efficacy Toxicity Designing a Nectin-4 ADC Intended to Address PADCEV® Unmet Needs

  12. Slide 12: CRB-701: Next Generation Site-specific Nectin-4 Targeting ADC

    CRB-701: Next Generation Site-specific Nectin-4 Targeting ADC MMAE = Monomethyl auristatin E ADCC = antibody-dependent cellular cytotoxicity. CDC = complement dependent cytotoxicity Source(s): Modified image from Corbus data on file; Corbus data on file Novel Nectin-4 Antibody ADCC + CDC functionali

  13. Slide 13: CRB-701: One Dose Every 3 Weeks Offers Advantages Over More Frequent Dosing

    CRB-701: One Dose Every 21 Days Offers Advantages Over More Frequent Dosing Source(s): Corbus data on file; PADCEV® Prescribing Information as of Dec 2019 PADCEV® CRB-701 Clinical Cycle Comparison Patient / Physician Convenience Combination Flexibility

  14. Slide 14: ASCO 2024 Update: Dose Escalation Study (China)

    ASCO 2024 Update: Phase 1 Dose Escalation Study (China) KEY ELIGIBILITY Age ≥ 18 years Advanced urothelial carcinoma or Nectin-4 positive Advanced solid tumors ECOG 0-1 Adequate organ function No uncontrolled diabetes No active CNS metastasis ESCALATION DESIGN Bayesian Optimal Interval (BOIN) design

  15. Slide 15: ASCO 2024 Update: Demographics & Key Characteristics

    ASCO 2024 Update: Demographics & Key Characteristics Characteristic Value Median age (range) 55 (35, 76) Sex (M/F) 29.7%, 70.3% ECOG PS 0,1, missing 8.1%, 89.2%, 2.7% Weight in Kg mean (range) 59.01 (36.0, 84.9) Prior therapies median (range) 4.0 (0,10) Creatinine clearance <60μ mol/L 29.7% Visceral

  16. Slide 16: ASCO 2024 Update: Safety and Dose Modifications

    ASCO 2024 Update: Safety and Dose Modifications Dose Modifications n Discontinuations 0 Reductions 0 Interruptions 1 CRB-701 continues to be well tolerated with mainly grade 1 or 2 AEs Still no DLTs or Grade 4 or 5 AEs observed to date including in the 4.5 mg/Kg cohort No additional grade 3 treatmen

  17. Slide 17: ASCO 2024 Update: TEAEs of Special Interest

    ASCO 2024 Update: TEAEs of Special Interest (<20% incidence) AE of special interest Grade Dose (n out of 37) Notes Skin rash 3 2.7 mg/Kg (n=1) Resolved after 8 days (no dose change) Skin rash 2 3.6mg/kg (n=1) Resolved after 5 weeks (no dose change) Skin rash 1 3.6 mg/kg (n=1) Resolved after 19 days

  18. Slide 18: ASCO 2024 Update: Pharmacokinetics

    ASCO 2024 Update: Pharmacokinetics Continuing to indicate differentiation from PADCEV Delivering higher amounts of ADC at the higher doses explored Consistently less free MMAE levels across all doses tested to date 21 Day PK Comparison %ADC %Free MMAE Cmax AUC0-21d Cmax AUC0-21d Enfortumab vedotin (

  19. Slide 19: Favorable Emerging Safety Profile vs. Nectin-4 ADC Competitors

    Favorable Emerging Safety Profile vs. Nectin-4 ADC Competitors 1 Rosenberg, et al., JCO, 2020 Apr 1; 38(10): 1041–1049, 2. NDA/BLA Multidisciplinary Review and Evaluation BLA 761137 PADCEV™ (enfortumab vedotin-ievx), 3. BicycleTx R&D day Dec. 2023, 4. Mabwell Announces 9MW2821 Clinical Data and Late

  20. Slide 20: ASCO 2024 Update: Dose Escalation Disease Responses

    ASCO 2024 Update: Phase 1 Dose Escalation Disease Responses Two of seven PRs are ongoing and unconfirmed. All of the previous (January ASCO GU data) PRs were confirmed.

  21. Slide 21: ASCO 2024 Update: Disease Response-mUC & Cervical

    ASCO 2024 Update: Disease Response-mUC & Cervical ≥ 1.2 mg/Kg ORR: 43% (3 of 7 at 2.6mg and 3.6mg/Kg) DCR: 86% ORR: 44% (4 of 9 at 3.6mg/Kg) DCR: 78% % Change by RECIST criteria Dose mg/kg NECTIN-4 3.6 3.6 2 .7 3.6 4.5 3.6 2.7 3.6 1.2 205 0 105 n.a. 271 220 190 293 175 3.6 3.6 3.6 1 .8 3.6 3.6 3.6 8

  22. Slide 22: ASCO 2024 Update: Swimmer Plots

    ASCO 2024 Update: Swimmer Plots

  23. Slide 23: ASCO 2024 Update: Summary Data

    ASCO 2024 Update: Phase 1 Summary Data Objective Response Rate in mUC at doses ≥ 1.2 mg/KG 44%: 4 out of 9 patients with PR’s (1 unconfirmed, DCR-78%) Objective Response Rate in Cervical at doses≥ 1.2mg/KG 43%: 3 out of 9 patients with PR’s (1 unconfirmed, DCR-86%) Dose for first observed SD 0.2 mg/

  24. Slide 24: CRB-701: A Differentiated Clinical Development Approach to Competitors

    CRB-701: A Differentiated Clinical Development Approach to Competitors Proprietary insights are driving indication selection for CRB-701 New reality of Padcev® + Keytruda® 1L therapy Under-served niche mUC populations remain and are attractive targets Emerging clinical data from current dose escalat

  25. Slide 25: CRB-701-01 Study Design (Corbus)

    CRB-701-01 Study Design (Corbus) Dose escalation (Dosing underway) Project Optimus (dose optimization) Dose expansion at RP2D Randomized to 2 doses of CRB-701 monotherapy Randomized to 2 doses of CRB-701 +CPI 1.8 mg/Kg 2.7 mg/Kg 3.6 mg/Kg 4.5 mg/Kg Bladder cancer niche population(s) Non-UC tumors: A

  26. Slide 26: Validation of Nectin-4 as a Tumor Associated Antigen beyond mUC

    Validation of Nectin-4 as a Tumor Associated Antigen beyond mUC References: 1. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.6017 2. Efficacy and safety of 9MW2821, an antibody-drug conjugate targeting Nectin-4, monotherapy in patients with recurrent or metastatic cervical cancer: A mult

  27. Slide 27: Expected Milestones

    ASCO-2024 Expected Q4-2024 Expected Q1-2025 Expected Milestones Q1-2024 First patient dosed in U.S. dose escalation study Clinical data update on China dose escalation study Complete U.S. dose escalation study Present U.S. dose escalation data

  28. Slide 28: Competitive Landscape in Cervical Cancer

    Competitive Landscape in Cervical Cancer Tivdak innovaTV-301(2) N=502 Median prior Tx=2 Tivdak initial approval(1) N=101 Median prior Tx=1 Mabwell (3) N=53 Cervical N=240 safety CRB-701 N=37 ORR 17.8% (TV) vs 5.2% (Chemo) (TV: CR 2.4%, PR 15.4%) 23.8% CR 7% PR17% 35.8% (cORR30.2%) Around 40-45% Ocul

  29. Slide 29: Cervical Cancer: Commercial Opportunity for CRB-701

    Cervical Cancer: Commercial Opportunity for CRB-701 14,000 new cervical cases in U.S. annually with 4,000 deaths1 Incidence in U.S. is still growing despite effective HPV vaccination due to: Low HPV screening rates in Asian and Hispanic women, lower vaccination in rural areas and lack of access to i

  30. Slide 30: CRB-701: Summary

    CRB-701: Summary Emerging clinical safety appears differentiated to PADCEV Clinical activity seen in mUC and cervical cancer patients 3rd generation ADC with improved linker stability, reduces MMAE in circulation

  31. Slide 31: CRB-913 Oral Cannabinoid Type-1 Inverse Agonist

    CRB-913 Oral cannabinoid Type-1 inverse agonist for superior incretin therapy in obesity

  32. Slide 32: The obesity landscape is evolving to address these issues

    The obesity landscape is evolving to address these issues Client asked if we could improve the style/layout of this slide Degree of weight loss Quality of weight loss Muscle loss » Single MOA Multiple orthogonal MOAs Tolerability » Injectables Oral small molecules Accessibility »

  33. Slide 33: The return of a clinically-validated obesity drug class

    The return of a clinically-validated obesity drug class CB1 Inverse Agonism

  34. Slide 34: CB1 is a Well Understood Receptor in Metabolism

    Source(s): Targeting the endocannabinoid system in diabesity: Fact or fiction?, Drug Discovery Today, Deeba et al. Mar 2021. CB1 is a Well Understood Receptor in Metabolism >9K papers in PubMed on CB1 and metabolism

  35. Slide 35: The CB1 MOA is Clinically Validated in Obesity

    The CB1 MOA is Clinically Validated in Obesity: Data From 1st Gen Drugs Source(s): 1. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia, Després et al, NEJM, Nov 2005. RIO-Lipids Phase 3 study Placebo (n=342); 5 mg rimonabant (n=345); 20 mg rimonabant (n=346) R

  36. Slide 36: Rimonabant Weight Loss Not Associated With Reduction of Lean Mass

    Body composition was measured with body DEXA in a subset of patients in RIO Lipids. Decreases in the rimonabant 20 mg group relative to placebo were observed in the total body mass (p<0.001), the total body fat mass (p=0.001) and the fat mass/total body mass ratio (p=0.007). There was no statistical

  37. Slide 37: Muscle-CB1 KO Leads to Increase In Muscle Mass in Obese Mice

    Muscle-cb1 KO Leads to Increase In Muscle Mass in Obese Mice (Gonzalez-Mariscal et al. 2019) Key finding: Muscle-CB1 KO mice… Increase in muscle mass and strength Increase in biomarkers of muscle growth Increase in mitochondrial metabolism Increase in energy expenditure Increase in calorie consumpti

  38. Slide 38: Next Generation CB1 Inverse Agonists are Peripherally Restricted

    INV-202 CRB-913 Next Generation CB1 Inverse Agonists are Peripherally Restricted Rimonabant Otenabant Ibipinabant Taranabant Source(s): Cinar et al 2020 First generation (2000-2007) Next generation (2020 onwards) Designed to target the brain with high BBB penetration  FDA rejection due to safety co

  39. Slide 39: Novo Nordisk Acquisition of Inversago Marks Return of CB1

    Single-dose INV-202 (25mg QD) N = 37 Adults with metabolic syndrome Weight loss in 28 days: -3.50 kg (INV-202) vs +0.55Kg (placebo) INV-202 (Inversago) a.k.a Monlunabant (Novo) a.k.a MRI-1891(NIH) Aug. 10, 2023 Novo Nordisk Acquisition of Inversago Marks Return of CB1 as an MOA in Obesity Source(s):

  40. Slide 40: Monlunabant Data Predicted for H2 2024

    Source: TD Cowen Research Report by Michael Nedelcovych May 8, 2024 “Novo has modeled the weight loss achieved in Phase I and expects to see 16-19% weight loss with single agent monlunabant at a mature time point (Phase Il obesity results anticipated in H2).” Monlabant (INV-202) Data Predicted for H

  41. Slide 41: How Could Such a Degree of Weight Loss Be Achieved From a CB1 Inverse Agonist?

    How Could Such a Degree of Weight Loss Be Achieved From a CB1 Inverse Agonist? Source(s): Inversago corporate presentation ClinicalTrials.gov ID: NCT05891834 Standard obesity endpoints + DEXA scan Standard inclusion and exclusion criteria 16 weeks once-daily tablet 50 mg/day = 2.5 pills of rimonaban

  42. Slide 42: CRB-913: Oral CB1 Inverse Agonist for Combination Therapy with Incretins

    Nov. 2023 CRB-913: Oral CB1 Inverse Agonist for Combination Therapy with Incretins

  43. Slide 43: CRB-913: Designed to be a Best-in-class Next Generation CB1 Inverse Agonist

    CRB-913: Designed to be a Best-in-class Next Generation CB1 Inverse Agonist Design Goals Best-in-class peripheral restriction Protect lean mass (muscle) Retain 1st gen efficacy Enhance efficacy of incretin analogs

  44. Slide 44: Oral CRB-913 is the Outcome of a Multi-year Medicinal Chemistry Campaign

    Ibipinabant (2004-2008) JD-5037 (2012-2018) / CRB-4001 (2018-2021) Completed Phase IIb (Solvay/BMS) Small, lipid soluble molecule High BBB penetration Oral Same backbone as Inversago compounds (MRI/INV family) CRB-4001 (JD5037) licensed from Jenrin in 2018 Extensive pre-IND studies carried out PK di

  45. Slide 45: CRB-913: Marked Lower Brain and Higher Peripheral Exposure Vs. Rimonabant

    Source(s): Morningstar et al. 2023 CRB-913: Marked ↓ Brain and ↑ Peripheral Exposure Vs. Rimonabant in Both Lean and Obese Mice 10 mg/Kg Co-administration with incretin analog does not affect brain penetration for CRB-913

  46. Slide 46: CRB-913: Higher Degree of Peripheral Restriction than Monlunabant or Rimonabant

    Source(s): *Morningstar et al 2023 and **Liu et al, 2021 Brain concentration (ng/g) single acute dose CRB-913 (lean mice) Monlunabant (lean mice) Rimonabant (lean mice) 10 mg/Kg 26* 319** 561* 1:12 1:21 CRB-913: Higher Degree of Peripheral Restriction than Monlunabant or Rimonabant

  47. Slide 47: CRB-913: Similar Weight Loss vs. Rimonabant at Same Daily Doses in DIO Mice

    Source(s): Morningstar et al 2023 CRB-913: Similar Weight Loss vs. Rimonabant at Same Daily Doses in DIO Mice

  48. Slide 48: CRB-913: Similar Weight Loss Despite Markedly Lower Brain Concentrations

    21-fold DIO mouse model (day 28) DIO mouse model with C57BL6/N mice (n=10) fed a continuous high fat diet for 22 weeks prior and during 28 days of treatment Brain collected 1 h post final dose (Cmax) Source(s): Company data on file. CRB-913: Similar Weight Loss Despite Markedly Lower Brain Concentra

  49. Slide 49: CRB-913 Demonstrates Significant Reduction in Body Fat Content but Not Lean Mass

    weight (g) Body Fat Lean Mass CRB-913 Demonstrates Significant Reduction in Body Fat Content but Not Lean Mass DIO mouse model with C57BL6/J mice (n=10) fed a continuous high fat diet for 22 weeks prior Body fat by MRI determined on Day 20 Source(s): Morningstar et al. 2023

  50. Slide 50: CRB-913: Enhanced Combo Effect with Semaglutide Or Tirzepatide

    CRB-913: Enhanced Combo Effect with Semaglutide Or Tirzepatide Source(s): Company data on file. DIO mouse model with C57BL6/J mice (n=10) fed a continuous high fat diet for 22 weeks prior and during 18 days of treatment (Similar effect also seen when CRB-913 was combined with liraglutide) Body weigh

  51. Slide 51: CRB-913 Reduces Food Consumption Alone or in Combination

    Source(s): Company data on file. Food Consumption CRB-913, semaglutide and tirzepatide each results in food intake reductions Significant further reductions in food consumption when CRB-913 is combined with semaglutide or tirzepatide (p=0.001) All cohorts P < 0.001 compared with vehicle DIO mouse mo

  52. Slide 52: CRB-913 Reverses Leptinemia Alone and in Combination

    CRB-913 Reverses Leptinemia Alone and in Combination with Semaglutide or Tirzepatide Source(s): 1 Leptin and the maintenance of elevated body weight, Pan and Myers, Nature Reviews, Jan 2018. Company data on file. The Role of Leptin The hormone leptin regulates food intake Normally, leptin signals sa

  53. Slide 53: CRB-913 Reduces Liver Fat Alone and in Combination

    vehicle CRB-913 (2.5 mg/Kg) semaglutide (10 nmol/Kg) CRB-913 (2.5 mg/kg) + semaglutide (10 nmol/Kg) tirzepatide (5 nmol/Kg) CRB-913 (2.5 mg/Kg) + tirzepatide (5 nmol/Kg) Liver fat CRB-913 Reduces Liver Fat Alone and in Combination with Semaglutide or Tirzepatide *liver oil red stain Source(s): Compa

  54. Slide 54: CRB-913: Clinical Development Pathway

    CRB-913: Clinical Development Pathway Q4 2024 H1 2025 H2 ‘25 – H1 ‘26 H2 ‘26 – H1 ‘27 SAD  MAD Monotherapy 28 days (3 doses) Co-admin with incretin analog

  55. Slide 55: CRB-913: Potential Clinical Usage

    1. Incretin analog therapy for insensitive/intolerant/high-risk patients 2. Combination with oral incretin agonists  potentially enhances efficacy OR improve tolerability 3. “Induction/maintenance” model: goal to potentially maintain weight loss post incretin analog therapy CRB-913: Potential Clini

  56. Slide 56: Expected Milestones

    Expected Milestones Produce drug for toxicology and clinical studies Q2-2024 Complete toxicology and IND enabling studies Q4-2024 FPI SAD/MAD Q1-2025

  57. Slide 57: Leadership, Upcoming Catalysts, Financials

    Leadership Upcoming Catalysts Financials

  58. Slide 58: Management Team

    Management Team Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since 2014. Prior senior financial management experience in emerging biotech and medical device companies. Christina Bertsch Head of Human Resources Accomplished senior human resource executive

  59. Slide 59: Board of Directors

    Board of Directors Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service in Washington, D.C. including Special Envoy to China; Former CEO of PhRMA. Avery W. (Chip) Catlin Director More than 25 years of senior financial leadership experience in life science companies; For

  60. Slide 60: Expected Corporate Milestones

    Expected Corporate Milestones First patient dosed: Q1-2025 First patient dosed: Q4-2024 Complete U.S. dose escalation study: Q4-2024 Present U.S. dose escalation data: Q1-2025 CRB-701 CRB-913 CRB-601

  61. Slide 61: Investment Summary

    Investment Summary $147M Cash, cash equivalents and investments as of June 30, 2024. Approximately 11.5M Common Shares Outstanding (12.5M Fully-Diluted Shares) Nectin-4 targeting ADC for treatment of solid tumors Oral CB1R inverse agonist to treat obesity TGFβ blocker Anti-⍺vβ8 integrin mAb for trea

  62. Slide 62: Connecting Innovation to Purpose

    Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation August 6, 2024

  63. Slide 63: Corbus Pharmaceuticals

    CORBUS %” PHARMACEUTICALS

  64. Slide 64: CRB-601 Potential best-in-class avb8 mAb

    CRB-601 Potential “best-in-class” ⍺vβ8 mAb

  65. Slide 65: CRB-601 has the Potential to Enhance Checkpoint Inhibition

    CRB-601 has the Potential to Enhance Checkpoint Inhibition Focus on adopting a precision-targeted approach Novel mechanism to target TGFb in the tumor microenvironment Large opportunity potential if POC is validated

  66. Slide 66: TGFb predicts poor clinical outcomes in a subset of cancer patients

    TGFβ predicts poor clinical outcomes in a subset of cancer patients 0 25 20 15 10 5 0.0 0.2 0.4 0.6 0.8 1.0 N = 8,461 cancers, multiple cell types Time (years) Overall survival, % Immunogenomic subtypes in cancer Source(s): Thorsson, et al. The Immune Landscape of Cancer, Immunity. 2018; 48:817 C1 C

  67. Slide 67: Targeting the Integrin avb8 Represents a Novel Approach to Regulating TGFb

    Targeting the Integrin ⍺Vβ8 Represents a Novel Approach to Regulating TGFβ Source(s): Huang et al., 2021. Recent progress in TGFβ inhibitors for cancer therapy.

  68. Slide 68: CRB-601 is Targeting Latent-TGFb by Blocking the Integrin avb8

    CRB-601 is Targeting Latent -TGFβ by Blocking the Integrin avb8 The integrin avb8 is expressed in the tumor microenvironment (TME) Latent-TGFb is also expressed in the TME CRB-601 is a blocking antibody preventing the interaction of these two proteins

  69. Slide 69: mAbs targeting TGFb activation in the clinic

    mAbs targeting TGFβ activation in the clinic Source(s): Company websites. Clinicaltrials.gov. Internal analysis. CRB-601 PF-06940434 SRK-181 ABBV-151 RG6440 MOA ⍺vβ8 ⍺vβ8 L-TGFβ GARP (TGFβ1) L-TGFβ Clinical Stage IND Cleared FPI Q4-2024 Phase 1/2 Phase 1 Phase 2 Phase 1 Indications Solid Tumors Soli

  70. Slide 70: CRB-601 Enhances Anti-PD-1 Therapy in Murine Tumor Models

    CRB-601 Enhances Anti-PD-1 Therapy in Checkpoint Inhibition Sensitive and Resistant Murine Tumor Models CRB-601: 10 mg/kg BIW Anti-PD-1: 10 mg/kg BIW 10 animals / group Animals randomized at 50-80 mm3 Comparisons across arms *p<0.05, ***p<0.001, ****p<0.0001 % TGI MC38 EMT6 4T1 Anti-PD-1 54 -8 6 CRB

  71. Slide 71: Blockade of avb8 with anti-PD-1 Increased TIL Populations in EMT6 Tumors

    Blockade of ⍺vβ8 in Combination with anti-PD-1 Increased TIL Populations in Immune Excluded EMT6 Tumors Source(s): Corbus data on file **** *** **** **** **** *** **** **** Ki67+CD4 T Cells Ki67+CD8 T Cells CD4 T Cells CD8 T Cells Tumor Size * *** * **** ** *** ** *** ** **** * **** * Treatment Days

  72. Slide 72: CRB-601 Reshapes The Landscape Of Effector T and NK Cells in MC38 Tumors

    CRB-601 Reshapes The Landscape Of Effector T and NK Cells in MC38 Tumors Source(s): Corbus data on file

  73. Slide 73: Applying a Proprietary Algorithm To Define The Clinical Focus for CRB-601

    Applying a Proprietary Algorithm To Define The Clinical Focus for CRB-601 A multi-parametric, immune-focused algorithm has refined indications for CRB-601 The combination of immune features and gene expression profiles have identified 9 indications for clinical priority High Low Quartiles Source(s):

  74. Slide 74: Patient Selection Strategies Will Enhance the Probability of Success

    Patient Selection Strategies Will Enhance the Probability of Success Source(s): Corbus proprietary analysis: Log2 fold change of Nectin-4 expression as a ratio to normal tissue Controls Ovarian Melanoma Breast Colon Prioritization of indications with differential gene expression vs. normal tissues w

  75. Slide 75: Expected Milestones

    Expected Milestones IND cleared January 2024 First patient dosed Q4-2024 Dose escalation and confirmation 1st Half of 2025

Corbus Pharmaceuticals Holdings — Investor Presentation (August 2024) on 6ix